454 Life Sciences Corporation

454 Life Sciences, a Roche Company

Jan Fredrik Simons

John Harris Leamon

Michael Egholm

Jan Berka

Gary James Sarkis

Birgitte Binderup Simen

Brian Christopher Godwin

Christine Lubeski

Zhoutao Chen

Stephen Kyle Hutchison

In one embodiment of the invention a method for detecting low frequency occurrence of one or more HIV sequence variants associated with drug resistance is describe that comprises generating cDNA species from RNA molecules in an HIV sample population; amplifying first amplicons from the cDNA species, wherein each amplicon comprises amplified copies and is amplified with a pair of nucleic acid primers that define a locus; clonally amplifying the amplified copies of the first amplicons to produce second amplicons that comprise an immobilized population of substantially identical copies from one of the amplified copies of first amplicons; determining a nucleic acid sequence composition from at least 100 of the immobilized populations in parallel on a single instrument; detecting one or more sequence variants that occur at a frequency of 5% or less in the nucleic acid sequence composition of the at least 100 immobilized populations; and correlating the detected sequence variants with variation associated with HIV drug resistance.

System and method for detection of HIV drug resistant variants

The present invention provides for a method of preparing a target nucleic acid fragments to produce a smaller nucleic acid which comprises the two ends of the target nucleic acid. Specifically, the invention provides cloning and DNA manipulation strategies to isolate the two ends of a large target nucleic acid into a single small DNA construct for rapid cloning, sequencing, or amplification.

Paired end sequencing

Growing community of inventors

Burlingame, CA, United States of America

Jan Fredrik Simons